Belvedere Trading Reduces $2K in Ginkgo Bioworks Holdings, Inc. ($DNA)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Belvedere Trading reduced its position in Ginkgo Bioworks Holdings, Inc. ($DNA), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Ginkgo Bioworks Holdings, Inc. after selling 177 shares during the quarter.
Ginkgo Bioworks Holdings, Inc. Stock Up 42.4%
Shares of Ginkgo Bioworks Holdings, Inc. ($DNA) traded around $9.91 on Saturday, up 42.4% for the day.
Ginkgo Bioworks Holdings, Inc. Earnings
Analysts Set New Price Targets
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Get Ginkgo Bioworks Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.